cri-one
Contents
100%
Your journey

FDA Rebuttals & Adwork (45-fda-rebuttles-and-adwork)

Inventory item: 8495 | SKU: 2076 | Line: Blueprints

Page: https://cri-one.com/45-fda-rebuttles-and-adwork.html

Owner and author: Christopher Gabriel Brown (CRI-ONE)

Record date: 8 October 2026

Approved public wording item: medical and regulatory wording follows the approved public description (descriptions-public).

1. The Record in Brief

FDA Rebuttals & Adwork is a regulatory-positioning and marketing package that assembles six health-science sub-projects - disease-mechanism research dossiers for diabetes, Alzheimer's and Parkinson's, a 300-disease mechanism-research database, the NeuroElement brain-chemistry system and the Health Recovery portfolio - with FDA/FTC positioning memos, red-team and steelman proofs, a compliance checklist and automated validation tooling (D:/special/_inventory/descriptions-public/8495.md). Its earliest dated disclosures are Christopher Gabriel Brown's depositions 133, 148, 201 and 373, each carried in the 2017 buyinvent.com catalog under the mark "copyright © 2017 chris g brown" (D:/manager/book-ocr-2017-invent-depositions/entries-clean.csv). Two pending USPTO applications are mapped to this product directly - U.S. Application No. 19/441,975 (filed 7 January 2026) and U.S. Application No. 19/445,644 (filed 12 January 2026) - and four more pending applications cover its bundled sub-projects (D:/Rebuttals/_registers/USPTO_REGISTER.json). The product was first listed as blueprint record SKU 2076 on the cri-one.com store on 31 August 2026 and is offered today on its own item page with a live card Buy button from 05:06 UTC on 8 October 2026. Copyright in every text, drawing, line of code and data compilation in the package belongs to its author from fixation, and the package carries the written notice "Copyright (c) 2026 Christopher Gabriel Brown. All rights reserved."

2. Proprietary - What Is Owned and How It Is Held

The package is a single folder of 812 files: six sub-project directories (Projects 10, 11, 12, 13, 22 and 33), three root tooling files (FDA_COMPLIANCE_CHECKLIST.md, validate_rebuttals.py, make_product_zips.py), a _product_zips directory of six pre-built archives, and the package index _TOC.md with its _TOC.html copy (generated 2026-10-06; it counts 810 content files). The file families on disk are:

FamilyCountExamples
Documentation (.md)4716 FDA_REBUTTAL memos, 6 red-team and 6 steelman proofs
Source code (.py)103validate_rebuttals.py, discovery runners, NeuroElement CLI
Vector drawings (.svg)4625 patent figure drawings, 12 sheets at 11x17
Data (.json)37discovery findings, brain-chemistry databases
Web pages (.html)37START_HERE, WEB_DESCRIPTION, store descriptions
Text, PDF, archives30 / 15 / 12paste-ready claims, USPTO receipts, product ZIPs

The package also carries patent-application drafts and paste-ready filing texts for the diabetes, Alzheimer's, Parkinson's, NeuroElement and Health Recovery subject matter, 6 essays, 6 rebuttal-note files, 4 safety disclaimers, 4 methodology disclosures and 6 CITATION.cff records (counts taken from the folder).

Ownership is sole. Every sub-project LICENSE names Christopher Gabriel Brown as exclusive owner, every patent document names him as sole inventor (D:/special/_inventory/descriptions-public/8495.md), and no assignment is of record. The owner's own license text (Evidence 3) states: "NO LICENSE IS GRANTED. No part of this Work may be copied, modified, distributed, sublicensed, sold, published, or otherwise transferred without the express written permission of the copyright holder." A buyer receives use only: the purchase term at https://cri-one.com/terms reads "When you buy, you buy the use of that blueprint only." Every Payment Link carries it as a required "Purchase term" the buyer must agree to at checkout (D:/special/crione-static/build_terms.py), and the item page repeats it beside the Buy button (D:/special/crione-static/site-inventory/inventory/item-8495/index.html).

The package is held under reasonable secrecy measures within 18 U.S.C. 1839(3). The full package is delivered only to paying buyers, by private time-limited download link sent by e-mail after payment (D:/special/crione-static/delivery-v2/deliver.py); the delivery file of record is 45-fda-rebuttles-and-adwork__2026-09-04.zip, 40,975,163 bytes (D:/special/crione-static/delivery-v2/product_deliverables.csv). The mutual NDA is published at https://cri-one.com/nda/ and its full text travels with every delivery e-mail. The public item page carries only the description.

3. First Art - The Earliest Dated Disclosure

DateRecordWhat it disclosesSource
2017Deposition 133, 2017 catalogReceptor-site measurement of dopamine, serotonin, adrenaline and histamineD:/manager/book-ocr-2017-invent-depositions/entries-clean.csv
2017Deposition 148, 2017 catalogHealthy-baseline chemistry and organ pH balance methodsame; IP register line 535
2017Deposition 201, 2017 catalogImmune-pathway insulin conceptsame; IP register line 871
2017Deposition 373, 2017 catalogToxicity and valence testing across diseases including Alzheimer'ssame; IP register line 1061
2017-11-24Invent Depositions, ISBN 978-1-979767-89-7Printed 2017 collection of Christopher Gabriel Brown's depositionsD:/manager/book-ocr-2017-invent-depositions/MANIFEST.md
2026-01-07U.S. Application No. 19/441,975Zinc-amino acid complexes, Alzheimer's subjectD:/USPTO Responses/Receipts/N417diabetes.pdf
2026-01-12U.S. Application No. 19/445,644Metal-amino acid complexes, Parkinson's subjectD:/USPTO Responses/Receipts/N417parkinsons.pdf

Deposition anchors (D:/Rebuttals/_registers/DEPOSITIONS_B.json, confirmed against the master IP register D:/special/82-alchemy-calc-two/1 light trigger.txt):

  • Deposition 373 (IP register line 1061; anchor: 2017 catalog): "toxic and valance testing to include but not limited to cancer and diseases like alzheimer's and substance abuse cessation aids." It is the screening method behind the Alzheimer's research dossier.
  • Deposition 201 (line 871; anchor: 2017 catalog): "immune systemic insulin. insulin medicine to magistrate through the auto immune system". It seeds the diabetes research dossier.
  • Deposition 148 (line 535; anchor: 2017 catalog): "can we figure out the chemistry in a healthy human, then make a ph balance inside each organ including the brain and thus making chemistry balance". It is the basis of the 300-disease research database.
  • Deposition 133 (line 369; anchor: 2017 catalog): "mission 1 diagnose changes at dopa mine serotonin adrenaline and histamine receptor sites in the central nervous system by using a similar method to diabetic blood testing." It is the brain-chemistry basis of NeuroElement.

Each of the four catalog entries carries the mark "copyright © 2017 chris g brown" and a buyinvent.com product image URL bearing its deposition number (D:/manager/book-ocr-2017-invent-depositions/entries-clean.csv). The origin-story records for all four are on file in D:/manager/book-ocr-2017-invent-depositions/origin-stories/.

Under 35 U.S.C. 102(a)(1), a printed publication or other public availability before a filing date is prior art against that filing. The 2017 depositions are dated public disclosures in the owner's name, so they stand against every later filer on the same subject matter. A challenger must produce a dated record earlier than these 2017 entries disclosing the same combination. None is of record.

Prior Art Considered and Distinguished

The site provenance record for SKU 2076 lists six portfolio-level references, all from the owner's own LED photon-recycling and portfolio prior-art tables (D:/special/_store/manager/_store/site-deploy-2026-09-23/archive-images-fix/crione-provenance.json; titles as recorded in D:/Rebuttals/_registers/PRIOR_ART_REGISTER.json). No product-specific search file exists in this package; its google_patents_search_list.txt indexes the owner's own application numbers, not third-party art.

ReferenceTitle as recordedDistinction
US 4,775,876Photon recycling light emitting diodeLED photon recycling; discloses no disease-mechanism dossier or regulatory memo
US 2010/0183919 A1Quantum dot ultracapacitor and electron batteryEnergy storage; no health-research content
US 2012/0305059 A1Photon recycling in an optoelectronic deviceOptoelectronics; no health-research content
US 6,175,719 B1Multi-Spot-Beam SatelliteSatellite payload; outside this subject matter
US 7,418,236 B2Extraterrestrial Communications SystemsSatellite-terrestrial communications; outside this subject matter
US 11,258,379 B2Quantum Noise Power DevicesEnergy harvesting; outside this subject matter

4. First to File - The USPTO Record

U.S. ApplicationFiledStatus of recordWhat it covers for this productSource
19/441,9752026-01-07Pending (Conf. [redacted]); reply recorded filed 2026-09-17Alzheimer's research dossier (Project 11)USPTO_REGISTER.json; Evidence 4
19/445,6442026-01-12Pending (Conf. [redacted]); reply recorded filed 2026-09-17Parkinson's research dossier (Project 12)USPTO_REGISTER.json; Evidence 5
19/555,5252026-03-03Pending (Conf. [redacted]); Filing Receipt 2026-08-13Bundled NeuroElement sub-project (Project 22)USPTO_REGISTER.json; Evidence 6
19/630,4442026-03-27Pending (Conf. [redacted])Bundled Health Recovery sub-project (Project 33)USPTO_REGISTER.json; Evidence 7
19/540,4532026-02-13Pending (Conf. [redacted]); Filing Receipt 2026-07-27Umbrella filing naming the disease discovery systems (Projects 10-13)USPTO_REGISTER.json
19/747,9492026-07-20Pending (Conf. [redacted])Diabetes and 300-disease subject matter (Projects 10, 13)USPTO_REGISTER.json

The register maps 19/441,975 and 19/445,644 to this product directly; the other four are mapped by the register to the sub-projects this package bundles. The USPTO acknowledgement receipt for 19/445,644 is kept inside the package itself, byte-identical to the receipt of record (SHA-256 bb5b87bad4927f62), as are the receipts for 19/555,525 (ca48a9d5f3d7e7f8) and 19/630,444 (2c8eededd0c15fa1). Each application is dated by its own effective filing date under the first-inventor-to-file system in force since 16 March 2013; none carries a benefit claim of record. Marking is correct under 35 U.S.C. 292 while these applications are pending, and the package LICENSE already carries the patent-pending notice for 19/441,975 (Evidence 3).

Marking line: Patent pending - U.S. Application Nos. 19/441,975 and 19/445,644.

5. First to Market - The Dated Public Offering

DateEventWhereSource
2014-03-05First Internet Archive capture of buyinvent.com, the 2017 catalog venueweb.archive.orgD:/manager/first-to-market/wayback_evidence.json
2017Depositions 133, 148, 201, 373 listed with copyright marksbuyinvent.com product lineD:/manager/book-ocr-2017-invent-depositions/entries-clean.csv
2017-11-24Invent Depositions first shippedCreateSpace / printD:/manager/book-ocr-2017-invent-depositions/MANIFEST.md
2026-08-31Blueprint record SKU 2076 created in Enterprise blueprintsold cri-one.com storeD:/manager/_store/export_catalog_product_20260831_201548.csv
2026-09-01Record re-created; kept in the 2026-09-07 catalog exportold cri-one.com storeD:/manager/export_catalog_product_20260907_110415.csv
2026-09-04Delivery file of record date-markedprivate delivery copiesD:/special/crione-static/delivery-v2/product_deliverables.csv
2026-10-08Item page publishedhttps://cri-one.com/45-fda-rebuttles-and-adwork.htmlD:/special/crione-static/site-inventory/inventory/item-8495/index.html
2026-10-08 05:06 UTCStripe card Payment Link (created 04:56:14Z) public as the Buy buttonitem pageD:/special/crione-static/delivery-v2/payment_links_ledger.live.json

The first new-site email campaign to US company prospects started at 03:55 UTC on 8 October 2026 from christopher@cri-one.com (D:/Rebuttals/_registers/FIRST_TO_MARKET_REGISTER.json).

6. Copyright

© 2017-2026 Christopher Gabriel Brown (CRI-ONE). All rights reserved.

The works covered are the expression in this package: the memo, essay, proof, checklist and description text; the 46 vector drawings, including 25 patent figure drawings and 12 reference, formulation and recipe sheets at 11x17; the 103 Python source files, including validate_rebuttals.py; the 37 JSON data compilations; the 37 web pages; and the 2017 deposition text from which the dossiers grew. Copyright arose on fixation of each work (17 U.S.C. 102(a)). It protects this expression, not the methods or compositions the works describe (17 U.S.C. 102(b)); method and composition are held by the pending applications in Section 4 and by confidentiality.

The corpus is anchored by the owner's verified Copyright Office registrations, among them TX 8-432-699 (cabbagestalk 11, effective 2017-01-13), TX 8-396-625 (abstract, 2017-05-09), TX 8-648-723 (2018, 2018-09-10), TX 8-657-127 (buy text, 2018-10-04) and TX 9-504-677 (estimated, 2025-05-06) - 19 verified certificates in all, effective 2010-10-01 to 2025-05-06 (D:/Rebuttals/_registers/COPYRIGHT_REGISTER.json). Registration is the gateway to suit for U.S. works (17 U.S.C. 411(a)), and a certificate made within five years of first publication is prima facie evidence of validity (17 U.S.C. 410(c)).

Human authorship: protection covers the human-authored expression and the author's selection, coordination and arrangement (U.S. Copyright Office registration guidance, March 2023). The protectable core here is human-authored: the concept, the numbered depositions written by Christopher Gabriel Brown, and his selection, arrangement and direction of the six sub-projects, the memos and the collateral into one package.

Notice practice: the 2017 catalog entries carry "copyright © 2017 chris g brown"; each of the six sub-project LICENSE files carries "Copyright (c) 2026 Christopher Gabriel Brown. All rights reserved." The notice defeats an innocent-infringer defense (17 U.S.C. 401(d)).

7. Firm Rebuttals

Challenge 1 - "This is not original; disease-chemistry research is old art."

Rebuttal. The record is dated. Depositions 133, 148, 201 and 373 were published in the owner's name in the 2017 catalog, each under a 2017 copyright mark (D:/manager/book-ocr-2017-invent-depositions/entries-clean.csv). The only references considered for SKU 2076 address LED photon recycling, energy storage, satellites and energy harvesting (Section 3); none discloses a disease-mechanism research dossier combined with FDA/FTC positioning memos, adversarial proofs and automated validation tooling. A challenger must produce a dated record earlier than 2017 disclosing the same combination. None is of record.

Challenge 2 - "Someone filed first."

Rebuttal. Six applications in the owner's name are of record from 7 January 2026 forward, each dated by its own USPTO receipt (Section 4). The 2017 depositions are prior art under 35 U.S.C. 102(a)(1) against any later filer on the same subject matter. A challenger must produce an effective filing date, or a public disclosure, earlier than the owner's dated records on the same combination. None is of record.

Challenge 3 - "No patent has issued, so there is nothing to respect."

Rebuttal. The owner holds pending applications 19/441,975 and 19/445,644, and "patent pending" marking is correct while they are pending (35 U.S.C. 292). Protection does not wait on examination: the package is held as a trade secret under 18 U.S.C. 1839(3), delivered only under the purchase term and NDA, and its expression is protected by copyright from fixation.

Challenge 4 - "The depositions were published, so the package is free to use."

Rebuttal. Publication of a one-line deposition in 2017 made it prior art against later filers; it did not publish the package. The 812-file package - memos, proofs, code, data and drawings - is delivered only to paying buyers by private link, and the buyer receives "the use of that blueprint only" (https://cri-one.com/terms). The LICENSE grants no license to copy, distribute or publish (Evidence 3).

Challenge 5 - "AI made it, so there is no copyright."

Rebuttal. The protectable core is human-authored: the 2017 depositions written by Christopher Gabriel Brown, the concept, and his selection, coordination and arrangement of six sub-projects and their regulatory overlay into one work. That is the expression the U.S. Copyright Office guidance of March 2023 protects. The owner's registration practice at the Copyright Office runs from 2010 through 2025 across 19 verified certificates.

Challenge 6 - "The dates can be faked."

Rebuttal. The dates rest on third-party records. Invent Depositions carries ISBN 978-1-979767-89-7, and its CreateSpace label records first shipment on 2017-11-24. The Internet Archive's own first capture of buyinvent.com is 2014-03-05 (D:/manager/first-to-market/wayback_evidence.json). The USPTO's electronic acknowledgement receipts fix 7 January 2026 (19/441,975, Patent Center 73872206) and 12 January 2026, 1:28:59 AM ET (19/445,644, Patent Center 73928275). Every evidence file is fingerprinted by SHA-256 in Section 8 and in D:/Rebuttals/_evidence/8495.sha256.

Challenge 7 - "This is an unlawful disease claim."

Rebuttal. The package is research and discovery IP. It makes no treatment claim, sells no consumable and pairs no consumable with its information. Its own memos establish that every biological statement is attributed to cited third-party literature and that the research is licensed business-to-business under NDA (D:/special/_inventory/descriptions-public/8495.md). The package executes that position with a seven-part compliance checklist, four safety disclaimers, four methodology disclosures and an automated checker that scans for forbidden strings, disclaimer presence and therapeutic-claim leaks (D:/special/45-fda-rebuttles-and-adwork/validate_rebuttals.py). The public item page uses the approved public wording.

Challenge 8 - "It is just an idea."

Rebuttal. The package is concrete work product: 103 Python source files, 37 JSON data compilations, 46 vector drawings including 25 patent figure drawings, application drafts and paste-ready filing texts for five subject areas, 6 objection-by-objection FDA/FTC memos, 6 red-team and 6 steelman proofs, and six pre-built product archives (Section 2). Three USPTO acknowledgement receipts sit inside it, byte-identical by SHA-256 to the receipts of record.

8. Evidence Index

#FileSHA-256 (first 16 hex)What it proves
1D:/special/_inventory/descriptions-public/8495.md82b330d2a2ef710cApproved public description; package contents and regulatory thesis
2D:/special/45-fda-rebuttles-and-adwork/_TOC.mdcf7c9dd48706f79ePackage index of 2026-10-06; file listing
3D:/special/45-fda-rebuttles-and-adwork/11-alzheimers-cure-discovery/LICENSEe19b40f334497eb2Copyright notice, exclusive ownership, no-license grant, patent-pending notice
4D:/USPTO Responses/Receipts/N417diabetes.pdfa2aa6ac673f1873fUSPTO receipt, 19/441,975, 2026-01-07
5D:/USPTO Responses/Receipts/N417parkinsons.pdfbb5b87bad4927f62USPTO receipt, 19/445,644, 2026-01-12; identical copy in package
6D:/USPTO Responses/Receipts/N417 (14).pdfca48a9d5f3d7e7f8USPTO receipt, 19/555,525; identical copy in package
7D:/USPTO Responses/Receipts/N417 (10).pdf2c8eededd0c15fa1USPTO receipt, 19/630,444; identical copy in package
8D:/Rebuttals/_registers/USPTO_REGISTER.jsonded33340c9582bd9Filing dates, statuses and product mapping
9D:/special/82-alchemy-calc-two/1 light trigger.txt2dcb359de3f1b56dMaster IP register; depositions 133, 148, 201, 373
10D:/manager/book-ocr-2017-invent-depositions/entries-clean.csvad3b87e885814dbb2017 catalog entries with 2017 copyright marks
11D:/special/_store/manager/_store/site-deploy-2026-09-23/archive-images-fix/crione-provenance.json4245280e5b3aea54Prior art considered for SKU 2076
12D:/manager/first-to-market/wayback_evidence.jsona0dde412013594b5Internet Archive first captures
13D:/manager/export_catalog_product_20260907_110415.csv12be9abf793c5f86Old-store blueprint record SKU 2076
14D:/special/crione-static/site-inventory/inventory/item-8495/index.htmld05aaf3a3bf10e3dItem page, purchase term, public wording
15D:/special/crione-static/delivery-v2/payment_links_ledger.live.json96abb64653254b86Card Payment Link created 2026-10-08T04:56:14Z
16D:/special/crione-static/delivery-v2/deliver.pya4ace02b3b7d341bPaid-only delivery by time-limited private link; NDA text with every delivery e-mail
17D:/special/crione-static/build_terms.py52a11d133023119dPurchase term required at checkout on every Payment Link

9. Notice Line

© 2017-2026 Christopher Gabriel Brown (CRI-ONE). All rights reserved. Patent pending - U.S. Application Nos. 19/441,975 and 19/445,644.

This invention blueprint: FDA Rebuttals and Adwork · $121M.
cri-one.com/45-fda-rebuttles-and-adwork.html
Also sold as part of Cri-One Health 2026 · $10.08B.
Payment is by bank transfer through Stripe.
Go to cart
Page 1 of 1
0% read